Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses
Research output: Contribution to journal › Journal article › Research › peer-review
The hepatitis C virus (HCV) genotype influences efficacy of interferon (IFN)-based therapy. HCV protease inhibitors are being licensed for treatment of genotype 1 infection. Because there are limited or no data on efficacy against HCV genotypes 2-7, we aimed at developing recombinant infectious cell culture systems expressing genotype-specific nonstructural (NS) protein 3 protease (NS3P).
| Original language | English |
|---|---|
| Journal | Gastroenterology Today |
| Volume | 141 |
| Issue number | 3 |
| Pages (from-to) | 1067-1079 |
| Number of pages | 13 |
| ISSN | 0969-0131 |
| DOIs | |
| Publication status | Published - 2011 |
- Carcinoma, Hepatocellular, Carrier Proteins, Cell Line, Tumor, Genotype, Hepacivirus, Hepatitis C, Humans, Indoles, Lactams, Liver Neoplasms, Molecular Sequence Data, Oligopeptides, Proline, Protease Inhibitors, Sulfonamides, Treatment Outcome, Viral Nonstructural Proteins
Research areas
ID: 40329614